Xcell Therapeutics엑셀세라퓨틱스

Xcell Therapeutics remains deeply loss-making, with its shares down sharply over the past year and a filing flagging possible market-cap-related designation risk.

Xcell Therapeutics makes cell culture media used to develop and produce cell and gene therapies, and it runs a GMP manufacturing facility in Yongin. Trailing twelve-month revenue is about ₩4.4B against an operating loss of about ₩11.3B, and the shares closed at ₩1,032 with a market capitalisation of about ₩17.8B. The data does not include any analyst ratings or price targets.

What stands out

• Trailing revenue is about ₩4.4B, but operating loss is about ₩11.3B, an operating margin near -259%.
• Free cash flow is about -₩10.7B, and borrowings of ₩4.6B exceed cash of ₩3.9B.
• Liabilities are about 192% of equity, and the 2025 year-end price-to-book ratio was 4.0.
• Shares are down 54.3% over one year and trade near the 52-week low of ₩951 (high ₩2,395).
• A filing dated 12 October 2026 flags potential administrative designation because market capitalisation is below ₩20B.

What to watch

• The 12 October 2026 market notice on possible administrative issue designation for market capitalisation below ₩20B.
• Next periodic results and any filings on funding, borrowings or capital raising, since cash is below borrowings.
• Recent 5%+ holding and insider shareholding reports, with no news headlines in the data to explain them.